Study to Predict Inflammation and Neurodegeneration in Primary Progressive Multiple Sclerosis

Study to Predict Inflammation and Neurodegeneration in Primary Progressive Multiple Sclerosis - SPIN-P

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49540

Enrollment

350

Registered

2020-04-03

Start date

2020-06-12

Completion date

Unknown

Last updated

2024-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PPMS Primary Progressive Multiple Sclerosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Aged 18 years or older - Diagnosis: fulfills the 2017 McDonald criteria for PPMS OR: Strong clinical suspicion of PPMS that has not (yet) fulfilled the 2017 McDonald criteria (e.g. symptoms have not yet lasted a full year, and/or dissemination in time and place have not yet been proven), but in which other possible diagnoses have been excluded - Patients have to be able to give informed consent.

Exclusion criteria

Exclusion criteria: Severe comorbidity with a life expectancy of 6 months or less.

Design outcomes

Primary

Measure	Time frame
The primary study parameters is the division of PPMS-patients into a PPi- and PPn- subgroup, as determined by an expertpanel of three MS-neurologists and based upon known clinical and radiological features of inflammation in MS as measured during the years of follow-up. Different other radiological and biological markers, measured early in the disease course, will be analyzed for their predictive value for this outcome.	—

Measure

Time frame

The primary study parameters is the division of PPMS-patients into a PPi- and PPn- subgroup, as determined by an expertpanel of three MS-neurologists and based upon known clinical and radiological features of inflammation in MS as measured during the years of follow-up. Different other radiological and biological markers, measured early in the disease course, will be analyzed for their predictive value for this outcome.

—

Secondary

Measure	Time frame
Several radiological and biological markers will also be analyzed for their prognostic value, for which we will use several measures of disease severity as outcome: the EDSS, (expanded disability scale), the T25FW (Timed 25 Foot Walk) and the SDMT (symbol digit modalities test).	—

Countries

Netherlands

Outcome results